查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837183

血管支架市场按产品类型、材料、输送系统、应用和最终用户划分－2025-2032年全球预测

Vascular Stent Market by Product Type, Material, Delivery System, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，血管支架市场将成长至 171 亿美元，复合年增长率为 6.09%。

关键市场统计数据
基准年 2024 106.5亿美元
预计年份：2025年 112.6亿美元
预测年份 2032 171亿美元
复合年增长率 (%) 6.09%

概述血管支架的现状，重点在于临床驱动因素、材料和输送创新，以及对医疗保健领导者的影响。

血管支架领域已进入一个新阶段，临床需求、材料科学和输送工程的交会融合，推动整个治疗路径的快速变化。血管成形术和置入术长期以来一直是冠状动脉和周边血管疾病的主要治疗方法，如今，旨在提高生物相容性、降低血管再阻塞和简化外科医生工作流程的器械级创新正在重新定义这些技术。同时，不断变化的患者群体和日益重视以价值为导向的医疗模式，正迫使医疗系统从长期疗效、报销影响和总成本等方面仔细评估器械的性能。

临床医师和医院管理者越来越期望医疗器材不仅能满足其急诊手术需求，还能与最新的影像处理集成，减少后续併发症，并在适当情况下支援门诊治疗。因此，製造商需要在工程技术进步与监管要求和采购实际情况之间寻求平衡，而支付者和政策制定者则在评估新技术如何融入现有的医疗保健系统。临床需求、技术进步和经济评估的交汇，为在实证医学、供应链韧性和相关人员参与的交汇点上，推动商业化进程的精细化策略决策奠定了基础。

在相关人员评估下一代血管支架时，了解材料、器械结构、传输系统、应用性能和最终用户环境之间的相互作用至关重要。本篇高阶主管分析综合了这些方面，旨在为产品开发、临床应用和打入市场策略提供切实可行的见解，以应对当前和近期医疗保健领域的挑战。

从材料突破到微创输送技术的进步，再到监管政策的演变，关键的变革性转变正在重塑血管支架的研发模式。

血管支架领域正经历一系列变革，这些变革正在重新定义器械设计、临床实践和商业化路径。材料科学的进步，包括可生物降解聚合物和精细化金属药物释放型，使得器械能够更好地适应血管生物力学，并以可控的方式降解或整合，从而解决了长期以来人们对慢性异物存在的担忧。同时，药物洗脱平台和表面工程技术的改进降低了血管再阻塞的风险，并将适应症扩展到更复杂的病变。

在手术操作方面，输送系统日益复杂，其外形设计针对迂曲的解剖结构进行了优化，并采用了提高部署精度的机制。这些工程改进使得个人化器械选择和定位成为可能，并可结合影像和术中引导，从而影响临床疗效和医保报销。值得注意的是，法律规范也在不断发展。监管机构越来越重视上市后证据和真实世界绩效指标，这会影响产品上市策略和生命週期管理。

经济和营运方面的影响同样重要。医疗系统越来越重视疗效比较和总医疗成本，这迫使医疗设备製造商除了临床疗效外，还要证明其后续价值。此外，患者的期望和人口结构变化，特别是老化和併发症群体，也迫使临床医生设计出既能保证持久性能又能降低手术风险的器械。综上所述，这些转变要求製造商、临床医生和支付方更紧密地合作，协调证据产生、推广途径和报销机制，以充分发挥新型血管支架创新技术的潜力。

评估美国关税于2025年生效后对血管支架供应链、采购惯例、生产营运和筹资策略的累积影响

美国将于2025年实施关税，这为血管支架相关人员的物流和采购计算引入了一个新的变数。目前，关税已经改变了进口零件和成品的相对成本结构，迫使製造商重新评估其采购决策和供应商合约。各公司重新审视了其生产基地，积极推动供应商多元化，并加快了关于近岸外包的讨论，以降低贸易政策波动带来的风险。

医院、心臟中心和门诊手术中心的采购团队随即重新评估了合约策略，强调签订能够确保价格稳定和供应的长期协议。这项转变要求在控製成本和保障临床供应连续性之间取得平衡，同时临床团队努力维持既定的器械选择路径和手术品质。同时，监管合规和品质监督仍然是重中之重，任何生产流程的转移或变更都需要经过严格的验证，以确保产品的可比性并满足国内外监管机构的要求。

随着时间的推移，关税也影响了合作模式和资本配置决策。一些製造商投资建设区域製造能力，以更有效率地服务于特定的本地市场；而另一些製造商则深化与本地供应商的关係，以缩短前置作业时间并降低库存风险。重要的是，这种累积效应不仅体现在交易层面，也体现在策略层面：企业重新评估了其应对挑战的策略，更加重视情境规划、双重采购和供应链透明度，以应对未来的政策变化，并确保患者能够获得关键的血管药物。

详细的細項分析揭示了产品类型、材料配置、给药方式、临床用途和最终用户设定如何决定设备策略。

细分市场层面的动态变化揭示了产品类型、材料组成、传输方式、临床应用和终端用户环境如何影响血管支架领域的研发重点和市场推广路径。支架可分为球囊扩张型和自动扩张型支架两种类型，二者在工程设计重点上有显着差异。球囊扩张型支架优先考虑精确的径向支撑力和病变部位的锚定，而自扩张式支架则强调与外周解剖结构的贴合性和持续的向外支撑力。此外，自动扩张型支架可细分为可生物降解和不可生物降解聚合物两种类型，分别用于实现临时锚定和长期减少异物负荷。

输送系统进一步区分了不同的价值提案。传统的裸金属支架与覆膜支架（提供屏障功能）和药物释放型支架（结合了机械支撑和药物预防新生内膜增生）形成对比。冠状动脉疾病需要最高的精准度和血管再阻塞控制，胃肠道疾病具有独特的管腔动力学和组织相互作用，而包括上下肢在内的周边动脉疾病则需要关注长节段的柔韧性、抗压性和抗疲劳性。最后，最终用户环境——门诊手术中心、心臟中心或医院——会影响器械规格和商业化策略。门诊使用的器械通常需要简化的工作流程和快速的恢復，而医院和心臟中心的应用场景可能更注重高级功能集和与混合手术室的整合。

了解这些细分维度之间的相互关係对于设计临床试验、优先考虑研发投资以及製定反映不同手术环境和护理模式的细微要求的市场推广策略至关重要。

从区域观点探讨美洲、欧洲、中东和非洲以及亚太市场的临床应用、监管路径和供应链策略

区域动态对血管支架技术的研发、监管和应用有显着影响，既带来了独特的机会，也带来了挑战。在美洲，先进的临床基础设施、高度集中的介入治疗专家以及不断完善的医保报销体系，共同创造了一个重视可靠临床证据和上市后疗效追踪的市场环境。因此，该地区的医疗设备上市通常强调随机对照试验和真实世界证据，以推动临床医生采纳和医疗照护机构的认可。

在欧洲、中东和非洲，监管协调工作和多样化的医疗保健系统资金筹措模式，共同构成了复杂的市场准入挑战。采购政策和卫生技术评估流程的差异，也要求製造商调整其价值提案和证据材料，以满足区域和国家决策者的要求。相较之下，亚太地区对医疗程序的庞大需求，以及新型医疗服务模式的快速普及，使得在地化生产能力和监管路径更加重要。这些监管路径需要结合具体临床数据，但同时也允许快速获得有条件核准。总而言之，这些区域差异影响着製造地、临床证据的生成以及商业性伙伴关係的策略重点，使得区域成为产品生命週期和市场推广计画的关键决定因素。

最终，采取细緻入微的区域性方法，将临床证据策略、监管参与和供应链架构与当地系统的期望相协调，将提高在不同医疗保健市场成功采用和持续使用的可能性。

血管支架产业的竞争格局和策略定位，重点在于创新、伙伴关係、卓越製造和商业化策略。

领先的血管支架开发商之间的竞争动态呈现出双重特征：一方面注重渐进式工程改进，另一方面则致力于颠覆性平台创新。拥有深厚製造传统的公司利用其规模优势、成熟的临床关係以及丰富的上市后数据来捍卫市场份额并争取有利的采购条款。同时，规模较小、反应更敏捷的参与企业则专注于细分市场差异化，例如新型可生物降解聚合物配方、独特的表面化学性质以及简化的给药机制，以期在临床和商业领域站稳脚跟。这些同行之间的合作通常以许可协议、联合开发伙伴关係和区域分销协议的形式展开，从而在控制研发风险的同时，实现前景广阔技术的快速推广。

投资正日益流向那些在手术效率、长期疗效和影像学相容性方面展现出显着优势的技术。与药物释放型动力学、生物可吸收基质设计和低轮廓输送导管相关的智慧财产权组合仍然是核心竞争优势。此外，近期趋势表明，企业越来越重视品质系统和供应链可追溯性，纷纷投资于序列化、生产分析和供应商审核，以满足监管要求和客户需求。策略併购和选择性联盟也正在重塑竞争格局，使企业能够拓展临床应用范围、增强技术能力并加速产品进入新地域市场的速度。

对于市场参与企业，规模、创新、监管合规和合作策略之间的相互作用，不仅决定了他们的短期竞争地位，也决定了他们在既重视临床卓越性又重视营运韧性的市场中的长期永续性。

为产业领导者提供可操作的建议，以加强研发合作、供应链韧性、监管参与和商业化效率。

行业领导者可以采取切实措施，将他们的洞察转化为可持续的竞争优势，并改善患者疗效。首先，将研发重点与具有临床意义的终点指标和医疗系统价值指标结合，可以加强医保报销谈判，并促进临床医师采纳相关技术。投资上市后证据产生和真实世界资料收集，可以检验疗效声明，并促进其融入临床诊疗路径。其次，应将供应链韧性提升为策略重点。双重采购、库存优化和区域生产方案可以实现对临床需求的快速反应，同时减轻政策变化和物流中断的影响。

第三，制定针对终端使用者环境（例如门诊手术中心、心臟中心和医院）的清晰商业化路径，可以使设备属性与手术要求和工作流程实际情况相匹配，从而提高产品普及率。第四，儘早积极地与监管机构就研究设计和上市后监测进行沟通，可以降低核准风险并加速产品进入市场。第五，考虑将技术差异化与销售能力结合的伙伴关係模式。共同开发和许可可以加快产品上市速度，并共用资源以产生实证医学证据。最后，由于实际操作经验是决定患者长期偏好的关键因素，因此应投资于强调手术效率和结果追踪的临床医生培训和推广计画。

这些措施共同构成了一个连贯的策略，平衡了技术领先性、商业性实用性和营运稳健性，使我们在快速发展的血管支架领域取得成功。

一套综合的调查方法，结合了专家访谈、二手证据整理、細項分析和情境规划，旨在提供可靠且可操作的洞见。

本分析的调查方法结合了专家定性访谈、系统性的二手研究和资料三角验证，以得出可靠且可验证的结论。主要资料来源包括对介入性心臟病专家、血管外科医师、采购负责人和法规事务专家的结构化访谈，并辅以器械工程师和生产营运主管的访谈。这些观点有助于我们从背景层面理解医疗机构的临床实务模式、器材性能优先顺序和采购考量。

本研究采用二手资料梳理法律规范、器材核准途径和已发表的临床证据，同时严格控制对检验资讯来源的依赖。在条件允许的情况下，整合定量资料以支持主题结论，并着重于多源资料交叉验证，以检验观察结果。分析方法包括交叉細項分析，以了解产品类型、材料、给药系统、应用和最终用户之间的相互作用；以及情境分析，以探讨关税等政策变化的影响。品质保证程序包括来源核实、同行评审和对研究结果的反覆完善，以确保研究结果清晰、相关且对决策者俱有可操作性。

伦理考量、专家贡献的保密性以及对应用调查方法的坚持，确保了结论以证据为基础，并对行业相关人员有战略意义。

总结部分重点阐述了技术创新、监管压力和供应链策略的交汇点，这些因素将塑造血管支架的未来。

总之，血管支架领域正处于曲折点，材料创新、改进的输送系统、监管预期和政策转变交织在一起，既带来了挑战，也带来了机会。包括可生物降解聚合物、增强型药物传输技术和更薄的输送系统在内的技术进步，正在拓展治疗冠状动脉、胃肠道和周边动脉疾病的临床套件，同时也对循证医学证据的生成和生命週期管理提出了新的考虑。政策发展和贸易行动凸显了供应链策略的重要性，鼓励各组织在不牺牲临床或品质标准的前提下，追求韧性和区域合作。

从策略角度来看，製造商和医疗服务提供者必须平衡临床疗效、经济价值和营运可靠性这三者的重要性。成功的关键在于采用整合式方法，将严谨的临床证据与适应性强的生产和采购模式、针对不同终端使用者环境的商业化策略以及积极的监管沟通结合。透过将投资集中于临床获益和系统价值融合的领域，产业参与者可以加速产品推广应用，改善患者预后，并建立永续的商业模式。本分析探讨的主题为高阶主管提供了蓝图，帮助他们在不断发展的血管支架领域中确定工作重点、管理风险并掌握机会。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 具有优化药物传递特性的生物可吸收血管支架的应用日益广泛
  • 无聚合物药物释放型支架的进展可降低冠状动脉介入治疗的发炎风险
  • 透过整合血管内成像和人工智慧技术，实现个体化的支架置入计划
  • 开发3D列印的患者特异性支架植入，以改善解剖结构匹配度及治疗效果。
  • 一种新型奈米涂层技术可促进支架内皮癒合并降低血管再阻塞率。
  • 远端桡动脉入路技术的进步影响了支架的设计，提高了手术安全性和舒适度。
  • 新型镁基生物可吸收支架在全球多个市场获得监管部门核准的数量增加
  • 新兴国家由于患者数量不断增加而面临的成本压力将推动专利到期药物释放型支架的普及。
  • 周边动脉疾病治疗需求的成长推动了髂动脉和股动脉支架设计的创新。
  • 将远端监测和数位疗法整合到支架置入术后的患者管理流程中。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 血管支架市场（依产品类型划分）

  • 球囊扩张型支架
  • 自动扩张型支架

9. 按材料分類的血管支架市场

  • 金属支架
  • 聚合物支架
    • 可生物降解聚合物
    • 不可生物降解聚合物

10. 依输送系统分類的血管支架市场

  • 裸金属支架
  • 覆膜支架
  • 药物释放型支架

第十一章 血管支架市场依应用领域划分

  • 冠状动脉疾病
  • 消化系统疾病
  • 周边动脉疾病
    • 下肢
    • 上肢

第十二章 血管支架市场（依最终用户划分）

  • 门诊手术中心
  • 心臟中心
  • 医院

第十三章 各地区血管支架市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 血管支架市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国血管支架市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • Amaranth Medical, Inc.
    • Artivion Inc.
    • B. Braun SE
    • Becton, Dickinson and Company
    • Biotronik SE & Co. KG
    • Blue Sail Medical Co., Ltd
    • Boston Scientific Corporation
    • Cardinal Health, Inc.
    • Cook Group Incorporated
    • Elixir Medical Corporation
    • Endologix LLC
    • iVascular, SLU
    • Kaneka Corporation
    • Kyoto Medical Planning Co., Ltd.
    • Lepu Medical Technology（Beijing）Co.,Ltd.
    • Lombard Medical Ltd.
    • Medtronic PLC
    • Meril Life Sciences Pvt. Ltd
    • Microport Scientific Corporation
    • Otsuka Medical Devices Co., Ltd.
    • Purple MicroPort Cardiovascular Pvt. Ltd
    • Sahajanand Medical Technologies Limited
    • Stryker Corporation
    • Terumo Corporation
    • Translumina GmbH
    • WL Gore & Associates, Inc.
Product Code: MRR-034B5003037F

The Vascular Stent Market is projected to grow by USD 17.10 billion at a CAGR of 6.09% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.65 billion
Estimated Year [2025] USD 11.26 billion
Forecast Year [2032] USD 17.10 billion
CAGR (%) 6.09%

Executive overview of the vascular stent landscape emphasizing clinical drivers, material and delivery innovations, and implications for healthcare leaders

The vascular stent landscape has entered a phase where clinical necessity, material science, and delivery engineering intersect to drive rapid change across care pathways. Angioplasty and stenting procedures, long established as core interventions for coronary and peripheral vascular disease, are being redefined by device-level innovation that targets improved biocompatibility, reduced restenosis, and simpler operator workflows. At the same time, evolving patient demographics and growing emphasis on value-based care are prompting health systems to scrutinize device performance across long-term outcomes, reimbursement impact, and total cost of care.

Clinicians and hospital administrators increasingly expect devices that not only meet acute procedural needs but also integrate with modern imaging, reduce downstream complications, and enable ambulatory delivery where appropriate. Consequently, manufacturers are balancing engineering advances with regulatory requirements and procurement realities, while payers and policy-makers assess how new technologies fit into existing coverage frameworks. This confluence of clinical demand, technological progress, and economic evaluation sets the stage for nuanced strategic decision-making, where commercialization plays out at the intersection of evidence generation, supply chain resilience, and stakeholder engagement.

As stakeholders evaluate the next generation of vascular stents, understanding the interplay between materials, device architecture, delivery systems, application-specific performance, and end-user settings becomes essential. This executive analysis synthesizes those dimensions to highlight actionable insights for product development, clinical adoption, and market access strategies that are responsive to current and near-term healthcare imperatives.

Major transformative shifts reshaping vascular stent development from materials breakthroughs to minimally invasive delivery advances and regulatory evolution

The vascular stent environment is experiencing a series of transformative shifts that together are redefining device design, clinical practice, and commercialization pathways. Advances in material science, including the maturation of biodegradable polymers and refined metallic alloys, are enabling devices that better match vascular biomechanics and degrade or integrate in a controlled manner, thereby addressing long-standing concerns about chronic foreign body presence. Concurrently, enhancements in drug-eluting platforms and surface engineering are reducing restenosis risk and expanding indications into more complex lesions.

On the procedural front, delivery systems are becoming more sophisticated, with profiles optimized for tortuous anatomy and mechanisms that improve deployment precision. These engineering changes are accompanied by imaging and intraprocedural diagnostics that allow personalized device selection and positioning, which in turn influence clinical outcomes and reimbursement narratives. Importantly, regulatory frameworks are also evolving; authorities are placing greater emphasis on post-market evidence and real-world performance metrics, which affects product launch strategies and lifecycle management.

Economic and operational forces are equally consequential. Health systems are emphasizing comparative effectiveness and total cost of care, prompting device manufacturers to demonstrate not only clinical efficacy but also downstream value. Finally, patient expectations and demographics-particularly aging populations with comorbidities-are pushing clinicians toward devices that balance durable performance with reduced procedural risk. Taken together, these shifts require manufacturers, clinicians, and payers to collaborate more intensively on evidence generation, adoption pathways, and reimbursement alignment to realize the full potential of new vascular stent innovations.

Assessment of the cumulative effects of United States tariffs enacted in 2025 on vascular stent supply chains, procurement practices, manufacturing operations, and sourcing strategies

The introduction of United States tariffs in 2025 introduced a new variable into the logistics and procurement calculus for vascular stent stakeholders. In the immediate term, tariffs altered the relative cost structure of imported components and finished devices, compelling manufacturers to reassess sourcing decisions and supplier agreements. Beyond the arithmetic of import duties, the policy change catalyzed broader strategic responses: firms re-examined production footprints, engaged in supplier diversification, and accelerated discussions about nearshoring to mitigate exposure to trade policy volatility.

Procurement teams within hospitals, cardiac centers, and ambulatory surgical settings responded by revising contracting strategies, emphasizing longer-term agreements that offered price certainty and supply assurances. These shifts required negotiation of terms that balanced cost containment with continuity of clinical supply, while clinical teams worked to preserve device preference pathways and procedural quality. Meanwhile, regulatory compliance and quality oversight remained central; relocating or altering manufacturing processes demanded rigorous validation to ensure product equivalence and to satisfy both domestic and international regulators.

Over time, the tariffs also influenced partnership models and capital allocation decisions. Some manufacturers invested in regional manufacturing capabilities to serve specific geographic markets more efficiently, while others deepened relationships with local suppliers to shorten lead times and reduce inventory risk. Importantly, the cumulative effect was not only transactional but strategic: organizations recalibrated their approach to resilience, placing greater emphasis on scenario planning, dual sourcing, and supply chain transparency to withstand future policy shifts and sustain patient access to critical vascular therapies.

In-depth segmentation analysis revealing how product type, material composition, delivery modality, clinical application, and end-user settings determine device strategy

Segment-level dynamics reveal how product type, material composition, delivery modality, clinical application, and end-user setting collectively shape development priorities and adoption pathways in the vascular stent domain. Devices classified by product type as balloon-expandable stents and self-expanding stents continue to diverge in engineering emphasis; balloon-expandable platforms prioritize precise radial force and lesion scaffolding, whereas self-expanding designs focus on conformability and chronic outward force for peripheral anatomy. Material choices reinforce these functional trade-offs: metallic stents, leveraging advanced alloys, deliver proven radial strength and radiopacity, while polymeric stents-split into biodegradable polymers and non-biodegradable polymers-open pathways for transient scaffolding and reduced long-term foreign body burden.

Delivery systems further differentiate value propositions. Traditional bare metal stents are contrasted with covered stents that provide barrier functions, and drug-eluting stents that combine mechanical support with pharmacologic prevention of neointimal hyperplasia. Application-specific requirements also drive segmentation: coronary artery disease demands utmost precision and restenosis control, gastrointestinal disease introduces unique luminal dynamics and tissue interactions, and peripheral artery disease-encompassing lower extremities and upper extremities-requires attention to long segment flexibility, compression resistance, and fatigue durability. Finally, end-user settings such as ambulatory surgical centers, cardiac centers, and hospitals influence device specifications and commercialization tactics; devices adopted in ambulatory contexts often need streamlined workflows and rapid recovery profiles, whereas hospital and cardiac center use cases may prioritize advanced feature sets and integration with hybrid operating suites.

Understanding how these segmentation dimensions interrelate is essential for designing clinical trials, prioritizing R&D investment, and tailoring market access approaches that reflect the nuanced requirements of distinct procedural contexts and care delivery models.

Regional perspectives on clinical adoption, regulatory pathways, and supply chain strategy across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics exert a powerful influence on how vascular stent technologies are developed, regulated, and adopted, producing geography-specific opportunities and constraints. In the Americas, a combination of advanced clinical infrastructure, concentrated centers of interventional expertise, and evolving reimbursement frameworks creates a market environment that rewards robust clinical evidence and post-market outcome tracking. Consequently, device launches in this region typically emphasize randomized and real-world evidence to accelerate clinician adoption and payer acceptance.

Across Europe, Middle East & Africa, regulatory harmonization efforts and diverse health system financing models create a complex mosaic for market entry. Variations in procurement policy and health technology assessment processes mean that manufacturers must adapt value propositions and evidence packages to satisfy regional and national decision-makers. In contrast, the Asia-Pacific region presents a mix of high-volume procedural demand and rapid adoption of new delivery models, with an increasing emphasis on localized manufacturing capabilities and regulatory pathways that can expedite conditional approvals while requiring contextually relevant clinical data. Taken together, these regional distinctions shape strategic priorities for manufacturing location, clinical evidence generation, and commercial partnerships, making geography a key determinant of product lifecycles and go-to-market planning.

Ultimately, a nuanced regional approach that aligns clinical evidence strategies, regulatory engagement, and supply chain architecture with local system expectations enhances the likelihood of successful adoption and sustained utilization across diverse health markets.

Competitive dynamics and strategic positioning across the vascular stent industry highlighting innovation, partnerships, manufacturing excellence, and commercialization tactics

Competitive dynamics among leading vascular stent developers are characterized by a dual emphasis on incremental engineering refinement and disruptive platform innovation. Companies with deep manufacturing heritage leverage scale, established clinical relationships, and extensive post-market datasets to defend share and negotiate favorable procurement terms. Simultaneously, smaller and more agile entrants focus on niche differentiation-such as novel biodegradable polymer formulations, unique surface chemistries, or simplified delivery mechanisms-to create clinical and commercial footholds. Collaboration between these cohorts often takes the form of licensing agreements, co-development partnerships, and localized distribution deals that enable rapid scaling of promising technologies while managing development risk.

Investment flows are increasingly directed toward technologies that demonstrate clear procedural efficiency gains, improved long-term outcomes, or strong compatibility with imaging modalities. Intellectual property portfolios around drug elution kinetics, bioresorbable matrix design, and low-profile delivery catheters remain central competitive assets. Moreover, recent trends show heightened attention to quality systems and supply chain traceability, with companies investing in serialization, manufacturing analytics, and supplier auditing to meet regulatory expectations and customer demands. Strategic M&A activity and selective partnerships are also shaping the competitive landscape, allowing firms to expand clinical reach, augment technological capabilities, or enter new geographic markets with reduced time-to-adoption.

For industry participants, the interplay of scale, innovation focus, regulatory compliance, and partnership strategy determines not only short-term competitive positioning but also long-term sustainability in a market that prizes both clinical excellence and operational resilience.

Actionable recommendations for industry leaders to strengthen R&D alignment, supply chain resilience, regulatory engagement, and commercialization effectiveness

Industry leaders can take concrete steps to translate insight into durable competitive advantage and improved patient outcomes. First, aligning R&D priorities with clinically meaningful endpoints and health system value metrics will strengthen reimbursement discussions and clinician adoption. Investing in post-market evidence generation and real-world data collection will validate performance claims and facilitate inclusion in care pathways. Second, supply chain resilience should be elevated to a strategic priority: dual sourcing, inventory optimization, and regional manufacturing options can reduce exposure to policy shifts and logistic disruptions while enabling faster response to clinical demand.

Third, developing clear commercialization pathways tailored to end-user settings-such as ambulatory surgical centers, cardiac centers, and hospitals-will improve uptake by matching device attributes to procedural requirements and workflow realities. Fourth, engaging with regulators early and proactively on study design and post-market surveillance reduces approval risk and accelerates market entry. Fifth, consider partnership models that combine technological differentiation with distribution strength; co-development and licensing can speed time-to-market and allow resource sharing for evidence generation. Finally, invest in clinician training and adoption programs that emphasize procedural efficiency and outcomes tracking, as hands-on familiarity remains a key determinant of long-term device preference.

Taken together, these actions create a cohesive strategy that balances technological leadership with commercial pragmatism and operational robustness, positioning organizations to succeed in a rapidly evolving vascular stent environment.

Comprehensive research methodology combining expert interviews, secondary evidence curation, segmentation analysis, and scenario planning to ensure robust actionable insights

The research approach underpinning this analysis integrates qualitative expert engagement with systematic secondary research and data triangulation to produce robust, defensible insights. Primary inputs included structured interviews with interventional cardiologists, vascular surgeons, procurement leaders, and regulatory affairs specialists, complemented by device engineers and manufacturing operations executives. These perspectives provided contextual understanding of clinical practice patterns, device performance priorities, and procurement considerations across care settings.

Secondary research was used to map regulatory frameworks, device approval pathways, and published clinical evidence, with careful curation to avoid reliance on unverified sources. Quantitative inputs were synthesized where available to support thematic conclusions, but the emphasis remained on triangulating multiple data sources to validate observations. Analytical methods included cross-segmentation analysis to understand how product type, material, delivery system, application, and end-user interact, and scenario analysis to explore the implications of policy shifts such as tariffs. Quality assurance procedures included source verification, expert review, and iterative refinement of findings to ensure clarity, relevance, and practical applicability for decision-makers.

Ethical considerations, confidentiality of expert contributions, and adherence to applicable research standards guided the methodology throughout, ensuring that conclusions are evidence-based and oriented toward strategic utility for industry stakeholders.

Concluding synthesis emphasizing the intersection of technological innovation, regulatory pressure, and supply chain strategy shaping the vascular stent future

In conclusion, the vascular stent sector stands at an inflection point where material innovation, delivery system refinement, regulatory expectations, and policy shifts intersect to create both challenges and opportunities. Technological advances such as biodegradable polymers, enhanced drug-elution technologies, and low-profile delivery systems are expanding the clinical toolkit for treating coronary, gastrointestinal, and peripheral arterial disease, while simultaneously raising new considerations for evidence generation and lifecycle management. Policy developments and trade measures have amplified the importance of supply chain strategy, prompting organizations to pursue resilience and regional alignment without sacrificing clinical or quality standards.

Strategically, manufacturers and healthcare providers must balance the imperatives of clinical performance, economic value, and operational reliability. Success will hinge on integrated approaches that combine rigorous clinical evidence with adaptive manufacturing and procurement models, targeted commercialization strategies for varied end-user environments, and proactive regulatory engagement. By focusing investments where clinical benefit and system value converge, industry participants can accelerate adoption, improve patient outcomes, and create sustainable commercial models. The themes explored in this analysis provide a roadmap for executives to prioritize initiatives, manage risk, and capture opportunities in the evolving vascular stent landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of bioresorbable vascular scaffolds with optimized drug delivery profiles
  • 5.2. Advances in polymer-free drug-eluting stents reducing inflammation risks in coronary interventions
  • 5.3. Integration of intravascular imaging and artificial intelligence for personalized stent placement planning
  • 5.4. Development of 3D printed patient-specific stent implants to improve anatomical conformity and outcomes
  • 5.5. Emerging nanocoating technologies enhancing endothelial healing and reducing restenosis rates in stents
  • 5.6. Rise of distal radial access techniques influencing stent design for improved procedural safety and comfort
  • 5.7. Increasing regulatory approvals of novel magnesium-based bioresorbable stents across multiple global markets
  • 5.8. Cost pressures driving adoption of off-patent drug-eluting stents in emerging economies with growing patient pools
  • 5.9. Expansion of peripheral artery disease treatment demand fueling innovation in iliac and femoral stent designs
  • 5.10. Integration of remote monitoring and digital therapeutics for post-stent implantation patient management pathways

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vascular Stent Market, by Product Type

  • 8.1. Balloon-Expandable Stents
  • 8.2. Self-Expanding Stents

9. Vascular Stent Market, by Material

  • 9.1. Metallic Stents
  • 9.2. Polymeric Stents
    • 9.2.1. Biodegradable Polymers
    • 9.2.2. Non-Biodegradable Polymers

10. Vascular Stent Market, by Delivery System

  • 10.1. Bare Metal Stents
  • 10.2. Covered Stents
  • 10.3. Drug Eluting Stents

11. Vascular Stent Market, by Application

  • 11.1. Coronary Artery Disease
  • 11.2. Gastrointestinal Disease
  • 11.3. Peripheral Artery Disease
    • 11.3.1. Lower Extremities
    • 11.3.2. Upper Extremities

12. Vascular Stent Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Cardiac Centers
  • 12.3. Hospitals

13. Vascular Stent Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Vascular Stent Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vascular Stent Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Amaranth Medical, Inc.
    • 16.3.3. Artivion Inc.
    • 16.3.4. B. Braun SE
    • 16.3.5. Becton, Dickinson and Company
    • 16.3.6. Biotronik SE & Co. KG
    • 16.3.7. Blue Sail Medical Co., Ltd
    • 16.3.8. Boston Scientific Corporation
    • 16.3.9. Cardinal Health, Inc.
    • 16.3.10. Cook Group Incorporated
    • 16.3.11. Elixir Medical Corporation
    • 16.3.12. Endologix LLC
    • 16.3.13. iVascular, S.L.U
    • 16.3.14. Kaneka Corporation
    • 16.3.15. Kyoto Medical Planning Co., Ltd.
    • 16.3.16. Lepu Medical Technology(Beijing)Co.,Ltd.
    • 16.3.17. Lombard Medical Ltd.
    • 16.3.18. Medtronic PLC
    • 16.3.19. Meril Life Sciences Pvt. Ltd
    • 16.3.20. Microport Scientific Corporation
    • 16.3.21. Otsuka Medical Devices Co., Ltd.
    • 16.3.22. Purple MicroPort Cardiovascular Pvt. Ltd
    • 16.3.23. Sahajanand Medical Technologies Limited
    • 16.3.24. Stryker Corporation
    • 16.3.25. Terumo Corporation
    • 16.3.26. Translumina GmbH
    • 16.3.27. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VASCULAR STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VASCULAR STENT MARKET SIZE, BY MATERIAL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VASCULAR STENT MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VASCULAR STENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VASCULAR STENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VASCULAR STENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VASCULAR STENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VASCULAR STENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VASCULAR STENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VASCULAR STENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VASCULAR STENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VASCULAR STENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VASCULAR STENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VASCULAR STENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VASCULAR STENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VASCULAR STENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VASCULAR STENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS VASCULAR STENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS VASCULAR STENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VASCULAR STENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VASCULAR STENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. GCC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GCC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GCC VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. GCC VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. GCC VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 274. GCC VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 275. GCC VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 276. GCC VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 277. GCC VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 278. GCC VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 279. GCC VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. GCC VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. GCC VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 282. GCC VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 283. GCC VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. GCC VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. BRICS VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. BRICS VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. BRICS VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 306. BRICS VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 309. BRICS VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 310. BRICS VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 311. BRICS VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. BRICS VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 313. BRICS VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 314. BRICS VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 315. BRICS VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. BRICS VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. G7 VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. G7 VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. G7 VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. G7 VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. G7 VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 322. G7 VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 323. G7 VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 324. G7 VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 325. G7 VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 326. G7 VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 327. G7 VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 328. G7 VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 329. G7 VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 330. G7 VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 331. G7 VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. G7 VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. NATO VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 334. NATO VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 335. NATO VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. NATO VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. NATO VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 338. NATO VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 339. NATO VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 340. NATO VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 341. NATO VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 342. NATO VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 343. NATO VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 344. NATO VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 345. NATO VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 346. NATO VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 347. NATO VASCULAR STENT MARKET SIZE, BY END USER